Just_Super/E+ via Getty Images Preamble My regular readers would know I look for value, growth, and quality in the companies I write about. I have not published much lately as it has been much harder to find good quality, value investments with sustainable growth. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) surfaced using Seeking Alpha's screener is interesting. The parameters I set in Seeking Alpha's screeners were: Long-term-debt-to-total-capital (between 0% to 50%) Past 3-years average revenue gro ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |---------------------------------------------------------------------------------------------------- ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Timothy Chiang - Capital One Pavan Patel - Bank of America Operator Greetings and welcome to the Amphastar Pharmaceuticals' First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-a ...

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.06%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.87 per share when it actually produced earnings of $0.88, delivering a surprise of 1.15%.Over th ...

EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024 Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA – May 8, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net revenues of $171.8 million for the first quarter ● GAAP net income of $43.2 million, or $0.81 per share, for the ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Amphastar Pharmaceuticals (AMPH) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Amphastar Pharmaceuticals (AMPH) . This company, which is in the Zacks Medical - Generic Drugs industry, shows potential for another earnings beat.This specialty pharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average sur ...

Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List due to downward revisions in earnings estimates over the last 60 days [1] Company Summaries - **Amphastar Pharmaceuticals, Inc. (AMPH)**: A bio-pharmaceutical company with a current year earnings estimate revised downward by 4.1% [1] - **BayCom Corp (BCML)**: The bank holding company for United Business Bank, with a current year earnings estimate revised downward by 12.4% [1] - **Diversified Healthcare Trust (DHC)**: Owns medical office and life science properties, senior living communities, and wellness centers, with a current year earnings estimate revised downward by 16.7% [1]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Amphastar Pharmaceuticals (AMPH) .Amphastar currently has an average broke ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q4 2023 Earnings Conference Call February 28, 2024 5:00 AM ET Company Participants Dan Dischner - SVP of Corporate Communications William Peters - CFO Tony Marrs - Executive Vice President of Regulatory Affairs and Clinical Operations Conference Call Participants Timothy Chiang - Capital One David Amsellem - Piper Sandler Glen Santangelo - Jefferies Operator Greetings, and welcome to the Amphastar Pharmaceuticals fourth quarter earnings call. [Operator Instructi ...